Clinical trials: Pediatric Hypertension
Hypertension
An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age
The purpose of this study is to evaluate in a randomized, double-blind fashion, the long-term safety, tolerability and efficacy profile of aliskiren compared to the active comparator enalapril in children, 6 - 17 years old with…
- Trial name
- NCT01151410
- Testing
- Aliskiren, Enalapril
- Where
- 36 sites in United States, Guatemala and 5 more
- Volunteers
- 208 people
- Sponsor
- Novartis Pharmaceuticals
Pediatric Hypertension
N-of-1 Trials In Children With Hypertension
The single patient (n-of-1) randomized trial is an underused approach to resolving therapeutic uncertainty by using a patient's own data to inform an individualized treatment plan.
- Trial name
- NICHE (NCT03461003)
- Testing
- NICHE method, Usual care, Amlodipine
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- The University of Texas Health Science Center, Houston
Pulmonary Arterial Hypertension
Bosentan in Children With Pulmonary Arterial Hypertension Extension Study
The main objective of the FUTURE 2 study was to assess the long-term safety and tolerability of the pediatric formulation of bosentan in children with idiopathic pulmonary arterial hypertension or familial pulmonary arterial…
- Trial name
- FUTURE 2 (NCT00319020)
- Testing
- Bosentan
- Volunteers
- 33 people
- Sponsor
- Actelion
Pulmonary Arterial Hypertension
A Clinical Study of to Confirm the Doses of Selexipag in Children With Pulmonary Arterial Hypertension
The purpose of this study to confirm the selexipag starting dose(s), selected based on pharmacokinetic (PK) extrapolation from adults, that leads to similar exposure as adults doses in children from greater than or equal to (>=)…
- Trial name
- NCT03492177
- Testing
- selexipag (Uptravi)
- Where
- 34 sites in United States, Belarus and 14 more
- Volunteers
- 63 people
- Sponsor
- Actelion
Hypertension
Atacand Dose Ranging in Hypertensive Pediatric Subjects 1 Year to Less Than 6 Years of Age
This is a dose ranging study of candesartan cilexetil in hypertensive pediatric subjects ages 1 to less than 6 years of age. It employs a double blind, randomized, dose ranging design intended for conduct as a multicenter trial.
- Trial name
- NCT00244621
- Testing
- candesartan cilexetil (Atacand)
- Where
- 38 sites in United States, Belgium and 8 more
- Volunteers
- 95 people
- Sponsor
- AstraZeneca
Hypertension, Pulmonary
A Study of Tadalafil in Pediatric Participants With Pulmonary Arterial Hypertension (PAH)
The main purpose of this study is to evaluate the safety and efficacy of tadalafil in pediatric participants with pulmonary arterial hypertension.
- Trial name
- NCT01824290
- Testing
- Tadalafil, ERA as specific PAH treatment
- Where
- 43 sites in United States, Austria and 12 more
- Volunteers
- 35 people
- Sponsor
- Eli Lilly and Company
Pulmonary Arterial Hypertension
A Pharmacokinetics Study for Pediatric Participants With Pulmonary Arterial Hypertension
The purpose of this study is to see how much study drug is in the blood of children with pulmonary arterial hypertension (PAH) after dosing to establish the correct dose for further clinical research.
- Trial name
- NCT01484431
- Testing
- Tadalafil- Tablet or Oral suspension
- Where
- 16 sites in United States, Canada and 4 more
- Volunteers
- 20 people
- Sponsor
- Eli Lilly and Company
Pediatric Glaucoma, Elevated IOP in Pediatric Patients
Study of Travoprost Ophthalmic Solution, 0.004% Compared to Timolol (0.5% or 0.25%) in Pediatric Glaucoma Patients
The purpose of this study is to evaluate the intraocular pressure (IOP)-lowering efficacy of Travoprost 0.004% POLYQUAD (PQ) ophthalmic solution compared to Timolol ophthalmic solution (0.5% or 0.25%) in pediatric glaucoma…
- Conditions
- Pediatric Glaucoma, Elevated IOP in Pediatric Patients, Ocular Hypertension in Pediatric Patients
- Trial name
- NCT01652664
- Testing
- Travoprost 0.004% PQ ophthalmic solution, Timolol, 0.5% or 0.25% ophthalmic solution, Travoprost Vehicle
- Volunteers
- 184 people
- Sponsor
- Alcon Research
Hypertension
Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
This double-blind 8 week study will evaluate dose response, efficacy (blood pressure lowering effect) and safety of aliskiren in children 6 - 17 years old with hypertension at low, mid and high weight-based doses.
- Trial name
- NCT01150357
- Testing
- Aliskiren (6.25/12.5/25 mg), Aliskiren (37.5/75/150 mg), Aliskiren (150/300/600 mg)
- Where
- 48 sites in United States, Belgium and 7 more
- Volunteers
- 267 people
- Sponsor
- Novartis Pharmaceuticals
Pediatric Hypertension With or Without CKD
Efficacy, Safety and Tolerability of Multiple Doses of Valsartan in Children With Hypertension With or Without CKD
To assess efficacy, safety and tolerability of valsartan when comparing two doses of valsartan in reducing and controlling blood pressure in children with hypertension with or without CKD.
- Trial name
- NCT01617681
- Testing
- VAL489
- Where
- 27 sites in Belgium, Brazil and 7 more
- Volunteers
- 127 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension
Olmesartan Pediatric Pharmacokinetic (PK) Study
Determine single dose pharmacokinetic parameters of olmesartan in pediatric patients with hypertension in ages 12 months - 16 years
- Trial name
- NCT00151814
- Testing
- Olmesartan medoxomil
- Where
- 5 sites in United States
- Volunteers
- 24 people
- Sponsor
- Daiichi Sankyo
Hypertension
Safety Study of Lisinopril in Children and Adolescents With a Kidney Transplant
The drug lisinopril is approved by the U.S. Food and Drug Administration for the treatment of high blood pressure, heart failure, and acute heart attacks in adult patients.
- Trial name
- PTN_LISINO (NCT01491919)
- Testing
- Lisinopril
- Where
- 7 sites in United States
- Volunteers
- 26 people
- Sponsor
- Uptal Patel
Hypertension
A Study of Azilsartan in Children From 6 to Less Than 16 Years Old With High Blood Pressure
The main aim of this study is to check for side effects from treatment with azilsartan and how well azilsartan controls blood pressure in children from 6 to less than 16 years old with high blood pressure.
- Trial name
- NCT05107960
- Testing
- Azilsartan (TAK-536)
- Where
- Japan
- Volunteers
- 5 people
- Sponsor
- Takeda
Diabetes Mellitus, Hypertension
Safety and Efficacy of Xenical in Children and Adolescents With Obesity-Related Diseases
Obesity is a condition affecting one-third off the U.S. population and is a major risk actor for the development of Type 2 diabetes, hyperlipidemia (increased levels of fat in the blood), hypertension (high blood pressure), and…
- Conditions
- Diabetes Mellitus, Hypertension, Metabolic Disease, Obesity
- Trial name
- NCT00001723
- Testing
- Orlistat
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Jack Yanovski
Hypertension
Study to Characterize the Long-term Clinical Experience of Atacand in Hypertensive Children Ages 1 to<11 Years (Hypertension in Pediatrics)
The HIP study is designed to follow the clinical experience of young hypertensive children receiving candesartan cilexetil (Atacand) who are between the ages of 1 and less than 11 years old.
- Trial name
- HIP (NCT00690612)
- Testing
- candesartan cilexetil
- Where
- 13 sites in Belgium, France and 4 more
- Volunteers
- 35 people
- Sponsor
- AstraZeneca
Hypertension
Study of Losartan in Pediatric Patients With Hypertension (MK-0954-337)
This study will explore the dose-response of losartan as well as the safety and tolerability in children from 6 months to 6 years of age.
- Trial name
- NCT00756938
- Testing
- losartan potassium
- Volunteers
- 101 people
- Sponsor
- Organon and Co
Glaucoma, Ocular Hypertension
Pharmacokinetic and Safety Study of Travoprost 0.004% in Pediatric Glaucoma Patients
The purpose of this study was to assess the safety and describe the steady-state plasma pharmacokinetic (PK) profiles of Travoprost ophthalmic solution, 0.004% (new formulation) following a once daily administration for 7 days in…
- Trial name
- NCT01658839
- Testing
- Travoprost ophthalmic solution, 0.004% (new formulation)
- Volunteers
- 25 people
- Sponsor
- Alcon Research
Pulmonary Hypertension
Sedation With Dexmedetomidine During Cardiac Catheterization
Clinical dose escalation drug trial to evaluate the effect of 3 different doses of dexmedetomidine on the pulmonary vascular bed in pediatric subjects with elevated pulmonary vascular resistance (PVR).
- Trial name
- NCT01072643
- Testing
- Dexmedetomidine
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Aruna Nathan
Pediatric Hypertension
A Phase 3 Pharmacokinetic Study of TAK-536 (Azilsartan) in Pediatric Patients 6 to Less Than 16 Years With Hypertension
The purpose of this study is to evaluate the pharmacokinetics and safety of a single dose of TAK-536 (azilsartan) in pediatric patients aged 6 to less than 16 years with hypertension.
- Trial name
- NCT02451150
- Testing
- Azilsartan
- Where
- 3 sites in Japan
- Volunteers
- 6 people
- Sponsor
- Takeda
Glaucoma
A Phase 3 Prospective, Randomized, Double-Masked, 12-Week, Parallel Group Study In Pediatric Subjects With Glaucoma.
To assess the effectiveness of latanoprost 0.005% ophthalmic solution dosed once-daily and timolol 0.5% dosed twice-daily in paediatric subjects of 18 years of age or under who are diagnosed with glaucoma.
- Trial name
- NCT00716859
- Testing
- Timolol, latanoprost
- Where
- 48 sites in United States, Belgium and 18 more
- Volunteers
- 139 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.